Catalyst Pharmaceutical

CPRX

Market cap $3.21B

The mean of analysts' price targets for Catalyst (CPRX) points to a 28.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Shares of Catalyst Pharmaceuticals, Inc. (CPRX) up 148% since 2022's first outlier institutional inflow signal.

Catalyst (CPRX) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.

Investors interested in stocks from the Medical - Drugs sector have probably already heard of Catalyst Pharmaceutical (CPRX) and United Therapeutics (UTHR). But which of these two stocks offers value investors a better bang for their buck right now?

Innovation is at its peak in the Zacks Medical-Drugs industry. INDV, CPRX, TBPH, RLMD and AVTX may prove to be good additions to one's portfolio.

EFXT, CPRX, GEV, STRA and BP have been added to the Zacks Rank #1 (Strong Buy) List on March 31st, 2026.

CPRX, STRT and BP made it to the Zacks Rank #1 (Strong Buy) value stocks list on March 31st, 2026.

The mean of analysts' price targets for Catalyst (CPRX) points to a 45.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Catalyst (CPRX) reported earnings 30 days ago. What's next for the stock?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.